Your session is about to expire
← Back to Search
HDR Brachytherapy for Prostate Cancer
Study Summary
This trial is looking at the feasibility and toxicity of using radioactive seeds to treat localized prostate cancer that has come back (recurred). There are other options to treat this, but there is no consensus on which is the best. This study will look at whether the radioactive seed treatment is safe and effective.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My prostate cancer is resistant to hormone therapy.I have undergone treatments like TURP, prostate surgery, or chemotherapy for prostate cancer.I am fully active or can carry out light work.My MRI shows my condition is near the urethra.My prostate cancer came back more than 30 months after radiation therapy, confirmed by a biopsy.My MRI shows my prostate cancer has returned but is only in the prostate.I have had radiation therapy for prostate cancer with specific dose ranges.My scans show no cancer spread to my abdomen, pelvis, or bones.My prostate is smaller than 50cc in volume.
- Group 1: HDR whole gland salvage treatment
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any sign-up opportunities for this trial currently available?
"According to clinicaltrials.gov, this particular trial is not recruiting applicants at present; the post was initially published on August 1st 2014 and last edited May 3rd 2022. However there are 2239 other trials in progress that require participants."
What are the research objectives of this investigation?
"Once brachytherapy has been administered, the primary outcome assessed over a three-month time frame will be Acute Gastrointestinal Toxicities. Additionally, researchers are evaluating for Acute Genitourinary Symptoms using the American Urological Association Symptom Index Score (IPSS), Late Gastrointestinal Toxicities with NCI CTCAE v.4.0 and finally, Late GU symptoms also via IPSS scoring."
Share this study with friends
Copy Link
Messenger